Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors

Jennifer Chan, MD, MPH
Published: Wednesday, Nov 15, 2017



Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

A phase II trial in patients with carcinoid and pancreatic NETs showed that treatment with cabozantinib was associated with objective tumor responses, as well as encouraging progression-free survival.

Chan says there is ongoing work to evaluate cabozantinib in a larger trial.
 


Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

A phase II trial in patients with carcinoid and pancreatic NETs showed that treatment with cabozantinib was associated with objective tumor responses, as well as encouraging progression-free survival.

Chan says there is ongoing work to evaluate cabozantinib in a larger trial.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x